BCL2L1 and neoplasm: The improvement we observed with BCL-XL inhibitor plus Cisplatin combinations was reflected in our studies using tumour-specific MCL-1 deletion to by-pass the fatal hepatotoxicity associated with co-administration of BCL-XL and MCL-1 inhibitors20.